Lisanti Capital Growth’s Denali Therapeutics DNLI Stock Holding History

Lisanti Capital Growth’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-98,130	Closed	-$7.7M	–	142
2021 Q2	$7.7M	Buy	+98,130	New	+$6.07M	0.95%	36
2021 Q1	–	Sell	-70,015	Closed	-$5.86M	–	145
2020 Q4	$5.86M	Sell	70,015 -81,275	-54%	-$4.91M	0.81%	53
2020 Q3	$5.42M	Buy	+151,290	New	+$4.56M	1%	54
2019 Q2	–	Sell	-73,605	Closed	-$1.71M	–	109
2019 Q1	$1.71M	Buy	+73,605	New	+$1.54M	0.61%	72

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lisanti Capital Growth's DNLI Position: Q3 2021 in Review

Lisanti Capital Growth sold out of Denali Therapeutics (DNLI) in Q3 2021, closing a stake of 98,130 shares — an estimated $7.7M sold.

Lisanti Capital Growth first reported a position in DNLI in Q1 2019 and held it in 4 quarters. The position peaked at $7.7M in Q2 2021. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

Lisanti Capital Growth reported no remaining Denali Therapeutics position as of Q3 2021 after selling out during the quarter.
Lisanti Capital Growth sold 98,130 Denali Therapeutics shares in Q3 2021, an estimated $7.7M.
Lisanti Capital Growth first reported a position in Denali Therapeutics in Q1 2019 and held it in 4 quarters.
Lisanti Capital Growth's Denali Therapeutics position peaked at $7.7M in Q2 2021.
214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Lisanti Capital Growth's 13F filing for Q3 2021, filed 3 Nov 2021.